Capital International Sarl Increases Stake in BioNTech SE (NASDAQ:BNTX)

Capital International Sarl grew its stake in BioNTech SE (NASDAQ:BNTX) by 1.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,058 shares of the company’s stock after acquiring an additional 310 shares during the quarter. Capital International Sarl’s holdings in BioNTech were worth $2,219,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its stake in shares of BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares during the last quarter. CWM LLC increased its stake in shares of BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after acquiring an additional 217 shares during the last quarter. Frazier Financial Advisors LLC acquired a new stake in shares of BioNTech in the 4th quarter worth $30,000. First Horizon Advisors Inc. acquired a new stake in shares of BioNTech during the 4th quarter worth about $38,000. Finally, Covestor Ltd increased its position in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BNTX shares. TD Cowen raised their price objective on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research report on Tuesday, May 7th. Evercore ISI started coverage on BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research report on Wednesday, June 26th. Finally, BMO Capital Markets lowered their target price on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, BioNTech presently has a consensus rating of “Hold” and a consensus target price of $111.70.

BioNTech Stock Up 1.5 %

Shares of BNTX traded up $1.26 during midday trading on Friday, hitting $85.94. The company had a trading volume of 264,744 shares, compared to its average volume of 691,346. The company’s 50-day simple moving average is $89.32 and its 200-day simple moving average is $91.59. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The firm has a market capitalization of $20.43 billion, a P/E ratio of 171.88 and a beta of 0.23. BioNTech SE has a 1 year low of $78.02 and a 1 year high of $125.83.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The company had revenue of $203.69 million during the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. As a group, sell-side analysts expect that BioNTech SE will post -2 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.